BIOMAT Database Logo BIOMAT Database Logo

Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. 2009

Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Department of Biochemistry, Faculty of Medicine of Sousse, Sousse, Tunisia. dalifms@yahoo.fr

BACKGROUND Alzheimer's disease (AD) is the leading cause of dementia. Currently, no definitive diagnostic test for AD exists. Cerebrospinal fluid (CSF) concentrations of amyloid beta (Abeta1-42) peptides and total tau proteins (T-tau) may serve as biomarkers for AD. OBJECTIVE The objective of this study was to investigate the usefulness of CSF Abeta1-42 and T-tau analyses in the diagnosis of AD with Tunisians. METHODS We focused on three groups originating from Central Tunisian that matched in age (range 48-85): healthy controls (n = 53), AD patients (n = 93) and non-Alzheimer (nAD) dementia (n = 35) patients. Abeta1-42 and T-tau levels were measured in CSF by sandwich enzyme-linked immunosorbent assay. RESULTS The ratio of T-tau/Abeta1-42 at baseline yielded a sensitivity of 85.3% for detection of AD and the specificity was 84.8% to differentiate controls and nAD dementia. CONCLUSIONS Our findings confirm the use of T-tau/Abeta1-42 ratio in the discrimination of AD patients from all other patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009483 Neuropsychological Tests Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Aphasia Tests,Cognitive Test,Cognitive Testing,Cognitive Tests,Memory for Designs Test,Neuropsychological Testing,AX-CPT,Behavioral Assessment of Dysexecutive Syndrome,CANTAB,Cambridge Neuropsychological Test Automated Battery,Clock Test,Cognitive Function Scanner,Continuous Performance Task,Controlled Oral Word Association Test,Delis-Kaplan Executive Function System,Developmental Neuropsychological Assessment,Hooper Visual Organization Test,NEPSY,Neuropsychologic Tests,Neuropsychological Test,Paced Auditory Serial Addition Test,Repeatable Battery for the Assessment of Neuropsychological Status,Rey-Osterrieth Complex Figure,Symbol Digit Modalities Test,Test of Everyday Attention,Test, Neuropsychological,Tests, Neuropsychological,Tower of London Test,Neuropsychologic Test,Test, Cognitive,Testing, Cognitive,Testing, Neuropsychological,Tests, Cognitive
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D003072 Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment. Overinclusion,Disorder, Cognition,Disorders, Cognition
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
February 2010, Clinical chemistry,
Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.
May 2004, Neurology,
Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.
November 2002, Archives of neurology,
Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Cerebrospinal fluid beta-amyloid and tau proteins for the diagnosis of Alzheimer disease.
March 2001, Archives of neurology,
Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
March 2007, Archives of neurology,
Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
March 2009, Archives of neurology,
Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization.
December 2009, Archives of neurology,
Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.
November 2001, Mechanisms of ageing and development,
Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer's disease.
January 2009, Dementia and geriatric cognitive disorders,
Mohamed Ali Smach, and Bassem Charfeddine, and Leila Ben Othman, and Turkia Lammouchi, and Hedi Dridi, and Souhir Nafati, and Afef Ltaief, and Soufien Bennamou, and Khalifa Limem
Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
January 1998, Journal of neural transmission. Supplementum,
Copied contents to your clipboard!